High pretreatment serum gamma-glutamyl transpeptidase predicts an inferior outcome in nasopharyngeal carcinoma

Min Luo; Wei Sun; Cheng Wu; Linli Zhang; Dongbo Liu; Wenwen Li; Qi Mei; Guoqing Hu

doi:10.18632/oncotarget.18798

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

High pretreatment serum gamma-glutamyl transpeptidase predicts an inferior outcome in nasopharyngeal carcinoma

Min Luo, Wei Sun, Cheng Wu, Linli Zhang, Dongbo Liu, Wenwen Li, Qi Mei _ and Guoqing Hu

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:67651-67662. https://doi.org/10.18632/oncotarget.18798

Metrics: PDF 2026 views | HTML 2566 views | ?

Abstract

Min Luo1, Wei Sun1, Cheng Wu1, Linli Zhang1, Dongbo Liu1, Wenwen Li1, Qi Mei1 and Guoqing Hu1

1Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan, People’s Republic of China

Correspondence to:

Qi Mei, email: [email protected]

Guoqing Hu, email: [email protected]

Keywords: nasopharyngeal carcinoma, serum marker, gamma-glutamyl transpeptidase, survival, prognosis

Received: September 20, 2016 Accepted: June 02, 2017 Published: June 28, 2017

ABSTRACT

Background: Gamma-glutamyl transpeptidase (GGT) which plays an important role in tumor initiation, invasion, drug resistance is strongly associated with poor prognosis in patients with cancers. This study was designed to estimate whether pretreatment serum GGT could predict the clinical outcome of nasopharyngeal carcinoma (NPC) patients.

Results: An optimal cutoff value was identified as 23 U/L for GGT. Univariate analysis and multivariate analysis demonstrated that elevated GGT was correlated with shorter local recurrence-free survival (LRFS) (HR, 4.163; 95% CI, 1.690-10.251; p=0.023), progression-free survival (PFS) (HR, 3.119; 95% CI, 1.955-4.976; p=0.031) and overall survival (OS) (HR, 2.811; 95% CI, 1.614-4.896; p=0.007).

Materials and Methods: We retrospectively analyzed data from 374 patients with NPC. Kaplan–Meier method was used to calculate and compare the prognosis. The Cox proportional hazards model was applied to carry out univariate and multivariate analyses.

Conclusion: Pretreatment GGT can be a novel and independent prognostic biomarker for patients with NPC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18798

Publication Alerts

Post-Publication Promotion

Research Papers:

High pretreatment serum gamma-glutamyl transpeptidase predicts an inferior outcome in nasopharyngeal carcinoma

Abstract